U.S. markets closed
  • S&P 500

    -75.65 (-1.46%)
  • Dow 30

    -475.84 (-1.24%)
  • Nasdaq

    -267.10 (-1.62%)
  • Russell 2000

    -39.43 (-1.93%)
  • Crude Oil

    +0.43 (+0.51%)
  • Gold

    -12.50 (-0.53%)
  • Silver

    -0.28 (-0.99%)

    -0.0085 (-0.79%)
  • 10-Yr Bond

    -0.0770 (-1.68%)

    -0.0104 (-0.83%)

    +0.0370 (+0.02%)
  • Bitcoin USD

    -3,680.34 (-5.44%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    +71.78 (+0.91%)
  • Nikkei 225

    +80.92 (+0.21%)

Does Medpace Holdings (MEDP) Have a Track Record of Robust Financial Performance?

Polen Capital, an investment management company, released its “Polen U.S. Small Company Growth Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund delivered 10.46% gross and 10.22% net of fees compared to a 12.75% return for the Russell 2000 Growth Index. The firm views the performance in many respects as evidence of the stability of its investment approach in the face of frequent and significant market swings. In addition, please check the fund’s top five holdings to know its best picks in 2023.

Polen U.S. Small Company Growth Strategy featured stocks such as Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter 2023 investor letter. Based in Cincinnati, Ohio, Medpace Holdings, Inc. (NASDAQ:MEDP) is a clinical research-based drug and medical device development services service provider. On February 20, 2024, Medpace Holdings, Inc. (NASDAQ:MEDP) stock closed at $384.14 per share. One-month return of Medpace Holdings, Inc. (NASDAQ:MEDP) was 29.54%, and its shares gained 96.07% of their value over the last 52 weeks. Medpace Holdings, Inc. (NASDAQ:MEDP) has a market capitalization of $11.816 billion.

Polen U.S. Small Company Growth Strategy stated the following regarding Medpace Holdings, Inc. (NASDAQ:MEDP) in its fourth quarter 2023 investor letter:

"Medpace Holdings, Inc. (NASDAQ:MEDP) is a mid-sized contract research organization (CRO) that services smaller biotech companies with venture/PE backing. Specifically, Medpace handles these companies' clinical trial-related R&D, and their business model is built upon being a full-service only solution. Given our quality orientation, it is particularly challenging to buy pharma and biotech companies due to their earnings losses and FDA risk. The company's impressive track record of robust financial performance—emphasizing stability, profitability, and well-above-average growth—offers us broad-based exposure to this industry. Medpace's business model is designed to minimize the binary risks associated with single-company FDA concerns or unprofitability, making it an optimal choice for us as we seek exposure to the groundbreaking innovation that comes with the biotech industry."

A clinical researcher in a lab examining a new biopharmaceutical product.

Medpace Holdings, Inc. (NASDAQ:MEDP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. At the end of the fourth quarter, Medpace Holdings, Inc. (NASDAQ:MEDP) was held by 38 hedge fund portfolios, up from 36 in the previous quarter, according to our database.

We discussed Medpace Holdings, Inc. (NASDAQ:MEDP) in another article and shared the list of stocks receiving a massive vote of approval from Wall Street analysts. In addition, please check out our hedge fund investor letters Q4 2023 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.